




## Validatie op de ACL-TOP


### dTT en Anti-Xa assay met Rivaroxaban calibrator




## DABIGATRAN dTT (DTR)




3  
Bepalende stap in stoltijd  
van de assay




4  
Dabigatran aanwezig




5  
Verlenging stoltijd



Scatter plot



Recovery plot







Bias and precision			
	ng/ml	Bias	CV %
LOW	44	-1,24	<b>23</b>
MID	205	-1,58	5,7
HIGH	360	-7,63	4,2
CRITERIA		< 10%	<12%



Linearity and Drift		
	Value	t
Intercept	-0,35	-0,1
Slope	0,985	-0,5
Nonlinearity	-0,00014	-0,4
Drift	-1,49	-1



## DABIGATRAN Verloop reagens




## DABIGATRAN Effect op de PT en APTT







# RIVAROXABAN

## anti-Xa assay met calibrator



# RIVAROXABAN

## EP-10







## RIVAROXABAN EP-10

Bias and precision			
	ng/ml	Bias	CV %
LOW	186	1	3,4
MID	287	15,3	3,4
HIGH	357	-1,7	3,3
CRITERIA		< 10%	<11,3%

Linearity and Drift		
	Value	t
Intercept	8,96	3,6
Slope	0,985	-0,4
Nonlinearity	-0,00207	-3
Drift	-0,06	-0,1



## RIVAROXABAN Effect op de PT en APTT





## SAMENVATTEND

### DABIGATRAN

- CV hoog bij lage concentraties
- Reagens zeer beperkt houdbaar na gebruik
- Normale APTT lijkt relevante levels uit te sluiten

### RIVAROXABAN

- Lineariteit verdient verdere aandacht
- Normale PT lijkt relevante levels **NIET** uit te sluiten

### WENSELIJK

- Correlatie van patiëntenmateriaal met MS-methode